Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this medical problem “through the creation of immune reprogramming technologies, which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases) and allergens,” a recent article reads. “While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s immune reprogramming platform, looks to address disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection and cancer. The technology, which utilizes an approach mimicking the way our bodies naturally induce tolerance to our own tissues, will initially be directed toward treating psoriasis, type 1 diabetes and skin allografting. In the interim, Aditxt has recently begun to commercialize its immune mapping technology, AditxtScore(TM), designed to provide individuals with a personalized profile of their immune system.”
To view the full article, visit https://ibn.fm/YvUot
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.net
TinyGems is part of the InvestorBrandNetwork